LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

Home・Listă Acțiuni・Krystal Biotech Inc

Krystal Biotech Inc

Deschisă

SectorSănătate

298.39 -2.53

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

297.98

Maxim

306.33

Indicatori cheie
By Trading Economics
Venit	4.5M 56M
Vânzări	9.3M 116M
P/E Medie Sector	41.829 51.415
EPS	1.83
Marjă de profit	48.069
Angajați	295
EBITDA	16M 55M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+3.17% upside

Dividende
By Dow Jones
Următoarele câștiguri	3 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	1.2B 9.2B
Deschiderea anterioară	300.92
Închiderea anterioară	298.39

Sentimentul știrilor

By Acuity

20%

80%

28 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

133.221 / 169.73 Suport & Rezistență

Krystal Biotech Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 mai 2026, 23:53 UTC

Achiziții, Fuziuni, Preluări

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mai 2026, 22:47 UTC

Acțiuni populare

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mai 2026, 22:16 UTC

Achiziții, Fuziuni, Preluări

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mai 2026, 22:00 UTC

Principalele dinamici ale pieței

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mai 2026, 18:09 UTC

Principalele dinamici ale pieței

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mai 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mai 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17 mai 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mai 2026, 23:07 UTC

Achiziții, Fuziuni, Preluări

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mai 2026, 23:06 UTC

Achiziții, Fuziuni, Preluări

UOB: Share Sale Agreements Entered With Singland Properties

17 mai 2026, 23:05 UTC

Achiziții, Fuziuni, Preluări

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mai 2026, 22:31 UTC

Achiziții, Fuziuni, Preluări

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mai 2026, 22:31 UTC

Achiziții, Fuziuni, Preluări

Prudential PLC to Acquire Stake for $389 Million

17 mai 2026, 22:30 UTC

Achiziții, Fuziuni, Preluări

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mai 2026, 16:27 UTC

Achiziții, Fuziuni, Preluări

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mai 2026, 15:26 UTC

Achiziții, Fuziuni, Preluări

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 22:17 UTC

Achiziții, Fuziuni, Preluări

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:59 UTC

Achiziții, Fuziuni, Preluări

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mai 2026, 21:50 UTC

Achiziții, Fuziuni, Preluări

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 20:19 UTC

Acțiuni populare

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mai 2026, 19:41 UTC

Achiziții, Fuziuni, Preluări

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mai 2026, 18:35 UTC

Câștiguri

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Comparație

Modificare preț

Krystal Biotech Inc Așteptări

Obiectiv de preț

By TipRanks

3.17% sus

Prognoză pe 12 luni

Medie 316 USD 3.17%

Maxim 378 USD

Minim 284 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruKrystal Biotech Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

10 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 10 analiști care au acordat evaluări ale acțiunilor Krystal Biotech Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

133.221 / 169.73Suport & Rezistență

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

28 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.